87 related articles for article (PubMed ID: 27378428)
1. MLF1IP is correlated with progression and prognosis in luminal breast cancer.
Huang DP; Luo RC
Biochem Biophys Res Commun; 2016 Sep; 477(4):923-926. PubMed ID: 27378428
[TBL] [Abstract][Full Text] [Related]
2. NCOA5 is correlated with progression and prognosis in luminal breast cancer.
Ye XH; Huang DP; Luo RC
Biochem Biophys Res Commun; 2017 Jan; 482(2):253-256. PubMed ID: 27847318
[TBL] [Abstract][Full Text] [Related]
3. A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer.
Yang F; Liu YH; Dong SY; Ma RM; Bhandari A; Zhang XH; Wang OC
Biochem Biophys Res Commun; 2016 Feb; 470(3):479-483. PubMed ID: 26820525
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Pofut1 and activated Notch1 may be associated with poor prognosis in breast cancer.
Wan G; Tian L; Yu Y; Li F; Wang X; Li C; Deng S; Yu X; Cai X; Zuo Z; Cao F
Biochem Biophys Res Commun; 2017 Sep; 491(1):104-111. PubMed ID: 28709865
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic Value of the Expression of Myeloid Leukemia Factor 1-Interacting Protein in Gastric Cancer and Its Regulatory Role in Tumor Progression].
Yang Z; Zhang H; Xu MY; Zhang XF; Wang YY; Ge ST; Geng ZJ; Song X; Li J; Hu JG; Zuo LG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 54(1):114-121. PubMed ID: 36647653
[TBL] [Abstract][Full Text] [Related]
6. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.
Ye J; Wang W; Xin L; Owen S; Xu L; Duan X; Cheng Y; Zhang H; Zhang S; Li T; Liu Y
Anticancer Res; 2017 Aug; 37(8):4549-4556. PubMed ID: 28739751
[TBL] [Abstract][Full Text] [Related]
7. MLF1IP promotes cells proliferation and apoptosis by regulating CyclinD1 in breast cancer.
Yang F; Wang YH; Dong SY; Chen CZ; Huang DP
Int J Clin Exp Pathol; 2017; 10(12):11554-11562. PubMed ID: 31966511
[TBL] [Abstract][Full Text] [Related]
8. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
9. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.
Tang J; Deng R; Luo RZ; Shen GP; Cai MY; Du ZM; Jiang S; Yang MT; Fu JH; Zhu XF
Breast Cancer Res Treat; 2012 Jul; 134(2):549-60. PubMed ID: 22585231
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
11. Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.
Xu J; Yang W; Wang Q; Zhang Q; Li X; Lin X; Liu X; Qin Y
Int J Clin Exp Pathol; 2014; 7(11):7915-22. PubMed ID: 25550832
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
[TBL] [Abstract][Full Text] [Related]
13. LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.
Li N; Zheng Y; Xuan C; Lin Z; Piao L; Liu S
Int J Clin Exp Pathol; 2015; 8(10):12893-900. PubMed ID: 26722481
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
16. Downregulated CDKN1C/p57
Qiu Z; Li Y; Zeng B; Guan X; Li H
Biochem Biophys Res Commun; 2018 Feb; 497(1):187-193. PubMed ID: 29428729
[TBL] [Abstract][Full Text] [Related]
17. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of long non-coding RNA CCAT1 is a novel biomarker of poor prognosis in patients with breast cancer.
Zhang XF; Liu T; Li Y; Li S
Int J Clin Exp Pathol; 2015; 8(8):9440-5. PubMed ID: 26464701
[TBL] [Abstract][Full Text] [Related]
19. [Relationship of c-FLIP(L) protein expression with molecular subtyping and clinical prognosis in invasive breast cancer].
Zang F; Wei X; Sun B
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):442-6. PubMed ID: 25327791
[TBL] [Abstract][Full Text] [Related]
20. Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.
Mo D; Li C; Liang J; Shi Q; Su N; Luo S; Zeng T; Li X
Int J Clin Exp Pathol; 2015; 8(8):9307-13. PubMed ID: 26464681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
